ROS-Responsive Nanoparticle Delivery of mRNA and Photosensitizer for Combinatorial Cancer Therapy
Nano Letters · 10.05.2023 · 23 (9) · 3661-3668
DOI: 10.1021/acs.nanolett.2c03784 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Letters, online erschienen am 24.04.2023. Verfasst von Hui Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China. Hauptthemen laut MEDLINE: Photochemotherapy, Nanoparticles, Lung Neoplasms. Die Arbeit wurde bisher 83-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Central University Basic Research Fund of China, Science, Technology and Innovation Commission of Shenzhen Municipality, American Lung Association.
Abstract (Originalsprache)
Messenger RNA (mRNA) therapy has shown tremendous potential for different diseases including cancer. While mRNA has been extensively used in cancer vaccine development as antigen or in cancer immunotherapy as immunomodulatory agent, the combination of mRNA therapy with photodynamic therapy has not been explored in cancer treatment. Herein, we report a reactive oxygen species (ROS)-responsive polymeric nanoparticle (NP) platform for first-in-field codelivery of mRNA and photosensitizer for effective cancer treatment. We developed ROS-responsive oligomer-based polymeric NPs and applied them to test a combination of p53 mRNA and indocyanine green (ICG). The ROS-triggered disassembly of the NPs could promote mRNA translation efficiency, whereby p53 expression induced apoptosis of lung tumor cells. Meanwhile, the released ICG could lead to generation of ROS under 808 nm laser irradiation to induce photodynamic therapy. The NP codelivery of p53 mRNA and ICG demonstrated an effective and safe anti-tumor effect in a lung cancer model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China.
- Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.
- State Key Laboratory of Organic Electronics and Information Displays & Institute of Advanced Materials (IAM), Nanjing University of Posts & Telecommunications, Nanjing 210023, China.
- Shenzhen Institute of Wuhan University, Shenzhen 518057, China.
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115 United States.
ORCID-Profile: Hui Zhou, Jinjun Shi
Förderung
- Central University Basic Research Fund of China
- Science, Technology and Innovation Commission of Shenzhen Municipality
- American Lung Association
- China Scholarship Council
Zitieren
APA
Zhou, H., Liao, Y., Han, X., Chen, D. S., Hong, X., Zhou, K., Jiang, X., Xiao, Y., & Shi, J. (2023). ROS-Responsive Nanoparticle Delivery of mRNA and Photosensitizer for Combinatorial Cancer Therapy. Nano Letters, 23(9), 3661-3668. https://doi.org/10.1021/acs.nanolett.2c03784
Vancouver
Zhou H, Liao Y, Han X, Chen DS, Hong X, Zhou K, et al. ROS-Responsive Nanoparticle Delivery of mRNA and Photosensitizer for Combinatorial Cancer Therapy. Nano Letters. 2023;23(9):3661-3668. doi:10.1021/acs.nanolett.2c03784
BibTeX
@article{Zhou2023,
author = {Zhou, Hui and Liao, Yuqin and Han, Xiangfei and Chen, Dean Shuailin and Hong, Xuechuan and Zhou, Kun and Jiang, Xingya and Xiao, Yuling and Shi, Jinjun},
title = {ROS-Responsive Nanoparticle Delivery of mRNA and Photosensitizer for Combinatorial Cancer Therapy},
journal = {Nano Letters},
year = {2023},
volume = {23},
number = {9},
pages = {3661--3668},
doi = {10.1021/acs.nanolett.2c03784}
}
EUVIMED